U.S. markets open in 1 hour 58 minutes
  • S&P Futures

    4,260.75
    +4.75 (+0.11%)
     
  • Dow Futures

    34,184.00
    +102.00 (+0.30%)
     
  • Nasdaq Futures

    14,372.75
    +18.50 (+0.13%)
     
  • Russell 2000 Futures

    2,334.40
    +3.20 (+0.14%)
     
  • Crude Oil

    73.12
    -0.18 (-0.25%)
     
  • Gold

    1,783.50
    +6.80 (+0.38%)
     
  • Silver

    26.24
    +0.19 (+0.73%)
     
  • EUR/USD

    1.1947
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    16.03
    -0.29 (-1.78%)
     
  • GBP/USD

    1.3900
    -0.0021 (-0.15%)
     
  • USD/JPY

    110.7210
    -0.1140 (-0.10%)
     
  • BTC-USD

    33,397.97
    -155.01 (-0.46%)
     
  • CMC Crypto 200

    795.78
    +9.17 (+1.17%)
     
  • FTSE 100

    7,119.87
    +9.90 (+0.14%)
     
  • Nikkei 225

    29,066.18
    +190.95 (+0.66%)
     

(BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties in connection with the proposed sale of the Company to Royal Philips (NYSE: PHG, AEX: PHIA).

On December 18, 2020, BioTelemetry announced that it had entered into a definitive merger agreement with Royal Philips. Under the terms of the acquisition agreement, the Company's shareholders will receive $72.00 per share in cash.

The investigation concerns whether the BioTelemetry board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for BioTelemetry shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts' projections for future earnings and revenue growth. Additionally, one Wall Street analyst had a $77.00 price target on the stock.

If you are a shareholder of BioTelemetry and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[Click here to join this action]

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/beat-alert-johnson-fistel-investigates-proposed-sale-of-biotelemetry-is-72-a-fair-price-301196017.html

SOURCE Johnson Fistel, LLP